Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.65 |
| ▸ | RORC | P51449 | 1/20 | 0.57 |
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265232 | 0.93 | PTGS2 (0.69) | PTGS2PTGS1ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL7677302 | 0.87 | PTGS2 (0.62) | PTGS2PTGS1KIF11 | |
| SCHEMBL10300269 | 0.87 | PTGS2 (0.62) | PTGS2PTGS1KIF11 | |
| SCHEMBL6725659 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6050771 | 0.82 | PTGS2 (0.72) | PTGS2PTGS1RORC | |
| SCHEMBL214545 | 0.82 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6050738 | 0.82 | PTGS2 (0.69) | PTGS2PTGS1 | |
| SCHEMBL8974296 | 0.82 | PTGS2 (0.60) | PTGS2PTGS1RORC | |
| SCHEMBL8974669 | 0.81 | PTGS2 (0.59) | PTGS2PTGS1RORCALDH1A1CYP3A4 | |
| SCHEMBL6726365 | 0.81 | PTGS2 (0.79) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1703905-B1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
| EP-1147101-B1 | REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | DAVIDSEN STEVEN K (US) | 2002-01-17 | — | — | US | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
| US-6288261-B1 | DRUGS FOR INHIBITION OF ENZYMES | ABBOTT LABORATORIES | 2001-09-11 | — | — | US | disclosed |
| US-6235786-B1 | RHEUMATIC DISORDERS; BONE DISORDERS; ORAL DISEASES; ANTIULCER AGENTS; ANTITUMOR AGENTS | ABBOTT LABORATORIES | 2001-05-22 | — | — | US | disclosed |
| WO-2000037433-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007060-A1 | Reverse hydroxamate inhibitors of matrix metalloproteinases | MMP1, MMP9, MMP3 | PTGS2 199/4885PTGS1 60/4885RORC 4547/4885 |
| US-20080269200-A1 | Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors | NFKBIA, IKBKB, IDO2 | PTGS2 35/4885PTGS1 118/4885RORC 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.